FibroBiologics Inc FBLG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
-
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
-
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
-
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
-
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
-
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
-
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Trading Information
- Previous Close Price
- $0.99
- Day Range
- $0.97–1.24
- 52-Week Range
- $0.62–9.60
- Bid/Ask
- $1.00 / $1.07
- Shares Outstanding
- 7.08M
- Market Cap
- $7.26M
- Volume/Avg
- 398,335 / 208,234
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 15
- Website
- https://www.fibrobiologics.com
Valuation
|
Metric
|
FBLG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FBLG
|
|---|---|
Quick Ratio | 1.59 |
Current Ratio | 2.64 |
Interest Coverage | −83.99 |
Quick Ratio
FBLG
Profitability
|
Metric
|
FBLG
|
|---|---|
Return on Assets (Normalized) | −152.72% |
Return on Equity (Normalized) | −490.09% |
Return on Invested Capital (Normalized) | −181.40% |
Return on Assets
FBLG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%Y&#^t@ | LOCK|#^M?L | $133B | |||
| Moderna Inc
MRNA
| LOCK|%##%@N^ | LOCK|cK | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g#knLCz | LOCK|Yk%WR | $83B | |||
| argenx SE ADR
ARGX
| LOCK|SNY%<@f | LOCK|cK | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sxF&TC | LOCK|F& | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&D?<Pm | LOCK|f#Kk | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@nC<s<c> | LOCK|$j%CD | $28B | |||
| Incyte Corp
INCY
| LOCK|W@WLDN | LOCK|?by | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?c>jPR | LOCK|#b | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|b<qqyx | LOCK|c% | $14B |
United States